Lrrc4 family mimic molecules and diagnostic uses thereof
AssigneeNeuracle Science Co., Ltd.
InventorsJae Young SEONG, Hoyun KWAK, Sitaek OH, Min-Hyeok LEE
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of LRRC4 family mimic molecules to determine the expression level of FAM19A5 protein in a subject. In some aspects, such mimic molecules can be used to identify and/or diagnose a subject suffering from or at risk of developing a disease or disorder associated with increased FAM19A5 protein expression. The present disclosure also provides methods of treating subjects identified and/or diagnosed using the methods provided herein.
Claims63
A method of determining an expression level of a family with sequence similarity 19, member A5 (“FAM19A5”) protein in a subject in need thereof, comprising:
- (i) contacting a biological sample of the subject with a Leucine Rich Containing 4 (“LRRC4”) family mimic molecule, which is capable of specifically binding to the FAM19A5 protein, and (ii) measuring the expression level of the FAM19A5 protein (“FAM19A5 protein expression level”) in the biological sample.
A method of diagnosing a disease or disorder in a subject in need thereof, comprising:
- (i) contacting a biological sample of the subject with a Leucine Rich Containing 4 (“LRRC4”) family mimic molecule, which is capable of specifically binding to a family with sequence similarity 19, member A5 (“FAM19A5”) protein, and (ii) measuring an expression level of the FAM19A5 protein (“FAM19A5 protein expression level”) in the biological sample.
A method of identifying a subject who is suitable for a treatment with an antagonist against a family with sequence similarity 19, member A5 (“FAM19A5”) protein (“FAM19A5 antagonist”), comprising:
- (i) contacting a biological sample of the subject with a Leucine Rich Containing 4 (“LRRC4”) family mimic molecule, which is capable of specifically binding to the FAM19A5 protein, and (ii) measuring an expression level of the FAM19A5 protein (“FAM19A5 protein expression level”) in the biological sample, wherein the subject is suitable for the treatment if the FAM19A5 protein expression level is increased compared to a reference (e.g., corresponding expression level in a subject who is not suffering from the disease or disorder).
A method of identifying a subject responsive to a treatment with an antagonist against a family with sequence similarity 19, member A5 (“FAM19A5”) protein (“FAM19A5 antagonist”), comprising (i) contacting a biological sample of the subject with a Leucine Rich Containing 4 (“LRRC4”) family mimic molecule, which is capable of specifically binding to the FAM19A5 protein, and (ii) measuring the expression level of the FAM19A5 protein (“FAM19A5 protein expression level”) in the biological sample, wherein the subject is responsive to the treatment if the FAM19A5 protein expression level is decreased compared to a reference (e.g., corresponding expression level in the subject prior to the treatment).
A method of treating a disease or disorder associated with an increased expression level of a family with sequence similarity 19, member A5 (“FAM19A5”) protein in a subject in need thereof, comprising administering to the subject a treatment for the disease or disorder and measuring an expression level of the FAM19A5 protein (“FAM19A5 protein expression level”) by contacting a biological sample of the subject with a Leucine Rich Containing 4 (“LRRC4”) family mimic molecule, which is capable of specifically binding to the FAM19A5 protein.
Dependencies are inferred from the claim text.